罗格列酮治疗非酒精性脂肪肝的疗效观察

Rosiglitazone for Patients with Nonalcoholic Fatty Liver:Observation of Curative Effects

目的:观察罗格列酮治疗非酒精性脂肪肝的疗效。方法:124例非酒精性脂肪肝患者(肝硬化期除外)随机分为治疗组(罗格列酮)与对照组(安慰剂),治疗24wk,比较2组疗效。结果:治疗组对肝功能、血糖、血脂的改善优于对照组(P<0.01);治疗组的总有效率(90.48%)明显高于对照组(60.66%,P<0.01);2组在安全性上无差异。结论:罗格列酮治疗非酒精性脂肪肝安全、有效。

OBJECTIVE： To investigate the efficacy of rosiglitazone in the treatment of patients with nonalcoholic fatty liver（NAFLD） .METHODS： A total of 124 patients with NAFLD（excluding those with cirrhosis） were randomly divided into rosiglitaone（RSG） treatment group and placebo group（control） for a treatment of 24wk.Then the curative effects in two groups were compared.RESULTS： As compared with placebo, RSG showed a better efficacy in the improvement of the liver function, levels of blood glucose and blood lipid（P （0.01） .The total effective rate in treatment group was significantly higher than in the control group（90.48% vs. 60.66% ）（P〈0.01） .No difference was noted between two groups in safety.CONCLUSION：RSG is effective and safe in the treatment of NAFLD.